The therapy can be used to treat patients with solid tumours. Credit: National Cancer Institute / Unsplash.

The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application submitted by Nuvation Bio for assessing NUV-868 to treat advanced solid tumours.

The BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor is indicated to treat tumours, including pancreatic cancer, ovarian cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

NUV-868 can also be used to treat patients with metastatic castration-resistant prostate cancer (mCRPC) and triple-negative breast cancer (TNBC).

Nuvation Bio founder, president and CEO David Hung said: “The clearance of our IND application for NUV-868 is an important milestone for Nuvation Bio as it marks the fourth IND in the last 14 months across our deep pipeline of innovative cancer therapeutics targeting multiple tumour types.

“We are encouraged by the selectivity and potentially improved tolerability demonstrated by NUV-868 in preclinical studies, and we look forward to advancing the programme into Phase I development in mid-2022.”

See Also:

Following the IND clearance, the company will now commence a Phase I/II trial of NUV-868 as a single agent and along with olaparib or enzalutamide in different types of tumours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The NUV-868-01 protocol is set to commence with a Phase I monotherapy dose-escalation study of the therapy in patients with advanced solid tumours.

A Phase Ib study will explore NUV-868 in combination with olaparib and enzalutamide followed by a Phase IIb study to study the efficacy and safety after determining the recommended Phase II combination dose.

Additionally, Nuvation Bio will start a Phase II monotherapy study in mCRPC patients to analyse safety and efficacy.

NUV-868, which hinders BRD4, a key BET family member, has been designed to be more selective for BD2 than BD1 for preventing the therapeutic limiting gastrointestinal (GI) and bone marrow toxicities, other BRD4 inhibitors.